tremelimumab,durvalumab,savolitinib 
pfizer,astrazeneca,orpathys,HUTCHMED
['kcsm,(-skcsm)', 'sclc', 'nsclc', 'calypso', 'tremelimumab', 'rcc,(-irccs),(-srcc),(-urcc)']
dr. powles presents calypso in advanced ccrcc. durva vs durva+treme(ctla4) vs durva+savo(meti) vs savo. meti savo did not demonstrate significant added activity whether tumors met driven or not (unlike nsclc). adding tremelimumab had modest impact at best #asco #kcsm
Medical oncologist - Developmental Therapeutics - NIH/NCI - opinions my own - retweet is not endorsement